LATE-BREAKING ABSTRACT: Bosentan in Pulmonary Hypertension associated with Fibrotic Idiopathic Interstitial Pneumonia:A Randomized, Double-Blind, Placebo-controlled Study
G. Keir, T. Corte, L. Parfitt, T. Maher, P. Marino, E. Renzoni, K. Dimopoulos, M. Gatzoulis, B. Madden, L. Howard, P. Corris, K. O'Reilly, B. Hope-Gill, S. Birring, A. Wells, S. J. Wort (London, Newcastle upon Tyne, Southampton, Cardiff, United Kingdom; Sydney, Australia)
Source: Annual Congress 2013 –Pulmonary circulation: treatment
Session: Pulmonary circulation: treatment
Session type: Oral Presentation
Number: 1779
Disease area: Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Keir, T. Corte, L. Parfitt, T. Maher, P. Marino, E. Renzoni, K. Dimopoulos, M. Gatzoulis, B. Madden, L. Howard, P. Corris, K. O'Reilly, B. Hope-Gill, S. Birring, A. Wells, S. J. Wort (London, Newcastle upon Tyne, Southampton, Cardiff, United Kingdom; Sydney, Australia). LATE-BREAKING ABSTRACT: Bosentan in Pulmonary Hypertension associated with Fibrotic Idiopathic Interstitial Pneumonia:A Randomized, Double-Blind, Placebo-controlled Study. Eur Respir J 2013; 42: Suppl. 57, 1779
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: